AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36295519
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (alfacalcidol 1 mcg/day)
Trial: 33468283
Drug: Behaviourally focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviourally focused nutrition education intervention (weekly sessions for 12 weeks)
Trial: 33990993
Drug: Anti-cancer drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-cancer drugs
Trial: 33990993
Drug: Conventional standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional standard therapies
Trial: 32241810
Drug: 30 mL/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL/kg/day feed advancement
Trial: 32241810
Drug: 18 mL/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mL/kg/day feed advancement (control)
Trial: 36217901
Drug: RP7214 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP7214 single dose (100, 200, and 400 mg QD)
Trial: 36217901
Drug: RP7214 multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP7214 multiple doses (200 and 400 mg BID for 7 days)
Trial: 36217901
Drug: RP7214 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP7214 single dose (200 mg) food effect study
Trial: 34192893
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg for 3.3 years
Trial: 35106590
Drug: HP501 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP501 (45 mg) administered over 10 days to hyperuricemic patients
Trial: 35106590
Drug: HP501 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP501 (doses from 5 to 60 mg)
Trial: 35106590
Drug: HP501 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP501 and febuxostat combination
Trial: 35106827
Drug: Non-anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anticoagulant therapy in patients with AF
Trial: 33106609
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin treatment
Trial: 33106609
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin treatment
Trial: 35857716
Drug: Amphetamine Extended-Release
RxNorm normalized name: amphetamine Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine Extended-Release Tablets (AMPH ER TAB) 5 mg starting dose, increased to 20 mg for 14±3 days before visit 5.
Trial: 33956056
Drug: Dapirolizumab pegol
RxNorm normalized name: Dapirolizumab pegol
DrugBank: Dapirolizumab pegol (DB16131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapirolizumab pegol (DZP) 6/24/45 mg/kg
Trial: 34784941
Drug: Propofol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5 mg/kg)
Trial: 32995892
Drug: Exenatide (EX)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide (EX) 10-20μg daily
Trial: 32995892
Drug: Combination (COM)
RxNorm normalized name: CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (COM) of Exenatide and Metformin
Trial: 32995892
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) 1500-2000 mg daily
Trial: 35910353
Drug: Ivermectin/albendazole 18/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin/albendazole 18/400 mg (1 tablet)
Trial: 35910353
Drug: Ivermectin 3
RxNorm normalized name: ivermectin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 3 mg (6 tablets)
Trial: 35910353
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg (1 tablet)
Trial: 32705834
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Jingui Shenqi pills and Suoquan capsules
Trial: 36297036
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of p-synephrine
Trial: 33390295
Drug: COVID-19 vaccine
RxNorm normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccine approval announced one week before the presidential election
Trial: 33390295
Drug: COVID-19 vaccine
RxNorm normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccine approval announced one week after the presidential election
Trial: 33390295
Drug: Endorsement by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endorsement by Dr. Anthony Fauci with pre-election vaccine approval
Trial: 33389320
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral pre-exposure prophylaxis and adherence support
Trial: 35334049
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (pH 6.0)
Trial: 33719503
Drug: Speech Intelligibility
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Speech Intelligibility Treatment (SIT)
Trial: 33719503
Drug: Hand‐Arm Bimanual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand‐Arm Bimanual Intensive Therapy Including Lower Extremities (PT)
Trial: 32343977
Drug: Antireflux ablation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antireflux ablation therapy (ARAT)
Trial: 32525464
Drug: Individualized blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized blood pressure lowering treatment
Trial: 32417382
Drug: IV Brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Brivaracetam 100 mg
Trial: 32417382
Drug: IV Brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Brivaracetam 200 mg
Trial: 35352835
Drug: Anifrolumab 300
RxNorm normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anifrolumab 300 mg Q4W
Trial: 35352835
Drug: Anifrolumab 150
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab 150 mg Q4W
Trial: 33496122
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine formula (CHMF)
Trial: 34215216
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) treatment for 12 weeks (transcranial, intranasal, neck and abdominal)
Trial: 34215216
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment with PBM devices after initial 12 weeks
Trial: 34665890
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC 7.5 mg
Trial: 34665890
Drug: Oral THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC 15 mg
Trial: 34903493
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection and oral citalopram
Trial: 34903493
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection and oral placebo
Trial: 34903493
Drug: Injective and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injective and oral placebo
Trial: 33063461
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) using 980 nm diode laser at 0.1 W output power, energy density of 4 J/cm2 delivered at six sites for 10 seconds each
Trial: 33063461
Drug: No adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjunctive treatment (Control Group)
Trial: 33128912
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g intravenous over 10 min followed by 1 g over 8 h)
Trial: 34726958
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg once daily for 24 months)
Trial: 34726958
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2 on day 1) plus Vinorelbine (25 mg/m2 on days 1 and 8; cis/vin) once every 3 weeks for four cycles
Trial: 32891163
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 4 IU/d on day 2 of the previous menstrual cycle until the trigger day
Trial: 35089613
Drug: Mirtazapine (MZ)
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine (MZ) 15–45 mg/day
Trial: 35089613
Drug: Sertraline (ST)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (ST) 25–200 mg/day
Trial: 32536683
Drug: G‐aenial immersed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐aenial immersed in coffee
Trial: 32536683
Drug: G‐aenial immersed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐aenial immersed in tomato sauce
Trial: 32536683
Drug: G‐aenial after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐aenial after polishing
Trial: 34887918
Drug: Microneedling plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling plus topical pimecrolimus 1%
Trial: 34887918
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus 1%
Trial: 33674858
Drug: Positive framing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive framing warning (e.g., '7 out of 10 people will not experience nausea')
Trial: 33674858
Drug: Negative framing
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative framing warning (e.g., '3 out of 10 people will experience nausea')
Trial: 33674858
Drug: General warning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General warning (e.g., 'a proportion of people will experience nausea')
Trial: 36267499
Drug: SOC+pegfilgrastim (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC+pegfilgrastim (0.6 mg subcutaneously on Day 1 and Day 8)
Trial: 33428221
Drug: Hyperbaric prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric prilocaine (60 mg intrathecal)
Trial: 33428221
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (12.5 mg intrathecal)
Trial: 36226998
Drug: Double acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double acupoint combination therapy (TN PC6 combined with ST36)
Trial: 34546300
Drug: Enteral L
RxNorm normalized name: PediaSure Enteral Liquid Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral L rhamnosus GG (1 × 10^10 colony-forming units) twice daily in the ICU (n = 1321)
Trial: 34546300
Drug: Enteral L
RxNorm normalized name: PediaSure Enteral Liquid Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral L rhamnosus GG
Trial: 35848844
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation associated with abdominal electrical stimulation (EE) via 8‐ and 20‐Hz Functional Electrical Stimulation (FES) of the abdominal muscles for 30 minutes daily for two weeks
Trial: 34781770
Drug: Wearable resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable resistance (WR) on lower legs during warm-up (200 g to 600 g)
Trial: 33755728
Drug: Continued subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued subcutaneous semaglutide 2.4 mg once weekly
Trial: 32897034
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of brensocatib
Trial: 32897034
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of brensocatib
Trial: 32897034
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg and 25 mg of brensocatib
Trial: 33497364
Drug: Tetravalent‐inactivated influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent‐inactivated influenza vaccine (TIV)
Trial: 32727225
Drug: Gamma tocopherol-enriched
RxNorm normalized name: gamma-Tocopherol
DrugBank: gamma-Tocopherol (DB15394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma tocopherol-enriched supplement
Trial: 33690909
Drug: Placebo 'anaesthetic'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 'anaesthetic' cream
Trial: 32007996
Drug: Exercise snacks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise snacks (6 × 1 min of resistance‐based activities) 3 times daily for 3 months with glutamine (0.5 g/kg/day)
Trial: 32007996
Drug: Exercise snacks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise snacks (6 × 1 min of resistance‐based activities) 3 times daily for 3 months with placebo
Trial: 33411466
Drug: Cefazolin monotherapy
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin monotherapy
Trial: 33411466
Drug: Cefazolin and
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin and aminoglycoside therapy
Trial: 34921690
Drug: Static computer-aided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static computer-aided implant surgery (s-CAIS)
Trial: 34921690
Drug: Conventional implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implant surgery (CIS)
Trial: 33430772
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg IVI in 100 ml normal saline (D group)
Trial: 34324113
Drug: No post-mastectomy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No post-mastectomy radiation therapy (no PMRT)
Trial: 32921065
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with IEPED)
Trial: 32438250
Drug: Pelvic suspension
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic suspension
Trial: 33196101
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction strategy for adalimumab, etanercept and ustekinumab
Trial: 33172225
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg (Group 2)
Trial: 35428982
Drug: ACE‐083 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE‐083 240 mg/muscle injected bilaterally every 3 weeks in the biceps brachii (BB) muscles
Trial: 35428982
Drug: ACE‐083 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE‐083 240 mg/muscle injected bilaterally every 3 weeks in the tibialis anterior (TA) muscles
Trial: 32614702
Drug: Docetaxel-based chemotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel-based chemotherapy
Trial: 35057416
Drug: Sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium phosphate (SP) supplementation (50 mg·kg−1 of FFM/day)
Trial: 39742913
Drug: HFNC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC at 60 L/min
Trial: 39742913
Drug: HFNC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC at 40 L/min
Trial: 32291309
Drug: Baseline (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (no therapy)
Trial: 32291309
Drug: HFNC (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC (20, 40, and 60 L/min)
Trial: 32291309
Drug: Conventional nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional nasal prongs at 5 L/min
Trial: 34019483
Drug: CAU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAU plus one dose of 0.1 mg/kg oral ondansetron
Trial: 34019483
Drug: CAU (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAU (oral rehydration therapy)
Trial: 34941339
Drug: Life Review
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life Review Therapy (LRT-HS), approximately 20 sessions including structured life review, narrative exposure, cognitive and behavioral elements.
Trial: 35410322
Drug: Paracetamol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol treatment
Trial: 34014688
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement and cognitive behavioral therapies plus adjunctive pharmacotherapy
Trial: 34014688
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement and cognitive behavioral therapies plus placebo
Trial: 35782469
Drug: Vaccine hesitancy
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine hesitancy due to misinformation, conspiracies, myths, and rumors about side effects of vaccination.
Trial: 39654273
Drug: Tenecteplase (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (0.25 mg/kg)
Trial: 32049857
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment (14 sessions over 2 weeks) with anti-depressant treatment
Trial: 32049857
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control group receiving only anti-depressant treatment
Trial: 35672690
Drug: liposomal MTP-PE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposomal MTP-PE in combination with ifosfamide
Trial: 36253042
Drug: Functional relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional relaxation (FR) therapy, implemented as group therapy, 12 sessions led by a certified physiotherapist once a week.
Trial: 36253042
Drug: Placebo relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo relaxation intervention for the same duration as the FR therapy.
Trial: 36253042
Drug: Functional relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional relaxation (FR) therapy
Trial: 35679461
Drug: Sodium hypochlorite
RxNorm normalized name: Sodium hypochlorite
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium hypochlorite solution (5.25%)
Trial: 35679461
Drug: Gel-based formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-based formulation of sodium hypochlorite
Trial: 35795100
Drug: Ultrasound-guided paravertebral
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided paravertebral block (PVB) followed by sufentanil patient-controlled intravenous analgesia (PCIA)
Trial: 35795100
Drug: Sufentanil patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil patient-controlled intravenous analgesia (PCIA) only
Trial: 35251438
Drug: Acupuncture (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (10 weekly sessions of manual Acupuncture)
Trial: 35251438
Drug: Sham Acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Acupuncture (10 weekly sessions of Sham Acupuncture)
Trial: 35598359
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg bid)
Trial: 35220180
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received intravenous tenoxicam and paracetamol, with morphine via patient‐controlled analgesia)
Trial: 32000786
Drug: Anopheles gambiae
RxNorm normalized name: ANOPHELES QUADRIMACULATUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anopheles gambiae s.l. tested by ELISA
Trial: 32141365
Drug: Passive music
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive music therapy during catheter placement and post-procedure (30-45 min during placement, twice a day for 30 min until discharge)
Trial: 35084480
Drug: Plinabulin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plinabulin, 40 mg
Trial: 35084480
Drug: Pegfilgrastim, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim, 6 mg
Trial: 33731209
Drug: GV-971 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV-971 (900 mg)